Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 25 versus ARMODAFINIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 25 versus ARMODAFINIL.
ADDERALL XR 25 vs ARMODAFINIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall XR is a combination of dextroamphetamine and amphetamine, which are non-catecholamine sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals and inhibit their reuptake, resulting in increased synaptic concentrations. This leads to CNS stimulation.
Armodafinil is a wakefulness-promoting agent. Its mechanism is unclear but may involve inhibition of dopamine reuptake, leading to increased extracellular dopamine levels. It also affects orexin, histamine, norepinephrine, and GABA pathways.
20-60 mg orally once daily in the morning; starting dose 20 mg, titrate weekly by 10-20 mg based on response and tolerability.
Adults: 150-250 mg orally once daily in the morning for narcolepsy or obstructive sleep apnea; 200-400 mg orally once daily for shift work disorder.
None Documented
None Documented
Clinical Note
moderateArmodafinil + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Armodafinil."
Clinical Note
moderateArmodafinil + Cyclosporine
"The serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil."
Clinical Note
moderateArmodafinil + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Armodafinil."
Clinical Note
moderateCyclophosphamide + Armodafinil
Dextroamphetamine: 10-13 hours; levoamphetamine: 11-14 hours. Effective half-life supports once-daily dosing with extended duration.
12–15 hours (terminal) in adults; longer in hepatic impairment (e.g., 20–30% increase with cirrhosis).
Renal: approximately 90% (30-40% unchanged, remainder as metabolites); fecal: minimal (<2%) via biliary elimination.
Renal: ~80% as metabolites (major: armodafinil acid, minor: modafinil sulfone); fecal: <1% unchanged; biliary: negligible.
Category C
Category C
CNS Stimulant
CNS Stimulant
"The metabolism of Armodafinil can be decreased when combined with Cyclophosphamide."